Foghorn Therapeutics Shows Promising Preclinical Data Across Multiple Cancer Programs
Event summary
- Foghorn Therapeutics presented new preclinical data for its Selective SMARCA2 inhibitor FHD-909, showing complete and durable tumor regression in combination with an anti-PD-1 antibody in syngeneic mouse models.
- Selective CBP degrader FHT-171 demonstrated strong anti-tumor activity and favorable tolerability in preclinical models of heavily pretreated ER+ breast cancer.
- Selective EP300 degrader outperformed clinical benchmark in preclinical multiple myeloma models, showing enhanced safety and efficacy.
- Robust degradation achieved with cereblon-based selective ARID1B degraders with potential for oral bioavailability.
The big picture
Foghorn Therapeutics' latest preclinical data underscores the potential of its chromatin-targeting approach in oncology, aligning with the broader industry trend towards precision medicine. The company's ability to demonstrate efficacy and safety across multiple difficult-to-treat cancers positions it as a key player in the development of next-generation cancer therapies. The strategic focus on selective degraders and inhibitors highlights Foghorn's commitment to addressing unmet medical needs in the oncology market.
What we're watching
- Clinical Translation
- How quickly Foghorn can transition these promising preclinical results into clinical trials and potential therapeutic applications.
- Competitive Positioning
- Whether Foghorn's selective degraders can maintain a competitive edge over existing and emerging therapies in the oncology space.
- Partnership Dynamics
- The extent to which collaborations, such as the one with Lilly, will accelerate the development and commercialization of Foghorn's pipeline.
Related topics